Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The Company's products are sold across the world, to wholesalers, retail pharmacies, hospitals, Government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in over six foreign countries. Its pharmaceutical products include chemically-synthesized drugs or small molecules, and products produced from biological processes. Its products in therapeutic classes: virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; metabolics; immunoscience, and cardiovascular. Its product F001287 is a preclinical, small-molecule IDO1-inhibitor. It offers an indoleamine 2, 3-dioxygenase (IDO) or tryptophan 2, 3-dioxygenase (TDO) discovery program that includes its IDO-selective, IDO/TDO dual and TDO-selective compound libraries.